{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:17Z","timestamp":1784822597948,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00943-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:45:56Z","timestamp":1777275956000},"page":"1557-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Early Intervention on Motor Milestone Achievement in Spinal Muscular Atrophy: Insights from Cure SMA Survey Data"],"prefix":"10.1007","volume":"15","author":[{"given":"Kendra A. K.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-1916","authenticated-orcid":false,"given":"Lisa","family":"Belter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Schroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"8","key":"943_CR1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/0883073807305668","volume":"22","author":"TW Prior","year":"2007","unstructured":"Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol. 2007;22(8):952\u20136. https:\/\/doi.org\/10.1177\/0883073807305668.","journal-title":"J Child Neurol"},{"issue":"1","key":"943_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"key":"943_CR3","doi-asserted-by":"publisher","unstructured":"Bowen BM, Truty R, Aradhya S, et al. SMA identified: clinical and molecular findings from a sponsored testing program for spinal muscular atrophy in more than 2,000 individuals. Front Neurol. 2021;12:663911. https:\/\/doi.org\/10.3389\/fneur.2021.663911.","DOI":"10.3389\/fneur.2021.663911"},{"issue":"4","key":"943_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","journal-title":"Neurol Clin"},{"key":"943_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12:124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"943_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000741.","journal-title":"Neurology"},{"issue":"2","key":"943_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/ejpn.1999.0181","volume":"3","author":"V Dubowitz","year":"1999","unstructured":"Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): An expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3(2):49\u201351. https:\/\/doi.org\/10.1053\/ejpn.1999.0181.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"943_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"943_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","volume":"178","author":"L Belter","year":"2024","unstructured":"Belter L, Taylor JL, Jorgensen E, et al. Newborn screening and birth prevalence for spinal muscular atrophy in the US. JAMA Pediatr. 2024;178(9):946. https:\/\/doi.org\/10.1001\/jamapediatrics.2024.1911.","journal-title":"JAMA Pediatr"},{"key":"943_CR10","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.2147\/IJGM.S369021","volume":"15","author":"L Ramos-Platt","year":"2022","unstructured":"Ramos-Platt L, Elman L, Shieh PB. Experience and perspectives in the US on the evolving treatment landscape in spinal muscular atrophy. Int J Gen Med. 2022;15:7341\u201353. https:\/\/doi.org\/10.2147\/IJGM.S369021.","journal-title":"Int J Gen Med"},{"issue":"18","key":"943_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"issue":"12","key":"943_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH Part 2): Secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(22)00339-8.","journal-title":"Lancet Neurol"},{"issue":"4","key":"943_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"key":"943_CR14","unstructured":"Health Resources and Services Administration. Spinal muscular atrophy\/about newborn screening. https:\/\/newbornscreening.hrsa.gov\/conditions\/spinal-muscular-atrophy. Accessed 17 Dec 2024."},{"issue":"2","key":"943_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-170292","volume":"5","author":"L Belter","year":"2018","unstructured":"Belter L, Cook SF, Crawford TO, et al. An overview of the Cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167\u201376. https:\/\/doi.org\/10.3233\/JND-170292.","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"943_CR16","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/acn3.51889","volume":"10","author":"CM Proud","year":"2023","unstructured":"Proud CM, Mercuri E, Finkel RS, et al. Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification. Ann Clin Transl Neurol. 2023;10(11):2155\u201360. https:\/\/doi.org\/10.1002\/acn3.51889.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"943_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200310","volume":"14","author":"M Schroth","year":"2024","unstructured":"Schroth M, Deans J, Arya K, et al. Spinal muscular atrophy update in best practices. Neurol Clin Pract. 2024;14(4):e200310. https:\/\/doi.org\/10.1212\/CPJ.0000000000200310.","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"943_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz O, Vill K, Pfaffenlehner M, et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Pediatr. 2024;178(6):540. https:\/\/doi.org\/10.1001\/jamapediatrics.2024.0492.","journal-title":"JAMA Pediatr"},{"issue":"7","key":"943_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","journal-title":"Nat Med"},{"issue":"4","key":"943_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.appdev.2004.06.005","volume":"25","author":"JL Bodnarchuk","year":"2004","unstructured":"Bodnarchuk JL, Eaton WO. Can parent reports be trusted?: validity of daily checklists of gross motor milestone attainment. J Appl Dev Psychol. 2004;25(4):481\u201390. https:\/\/doi.org\/10.1016\/j.appdev.2004.06.005.","journal-title":"J Appl Dev Psychol"},{"issue":"6","key":"943_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/dmcn.15816","volume":"66","author":"S Warschausky","year":"2024","unstructured":"Warschausky S, Gidley Larson JC, Raghunathan T, et al. Longitudinal caregiver-reported motor development in infants born at term and preterm. Dev Med Child Neurol. 2024;66(6):725\u201332. https:\/\/doi.org\/10.1111\/dmcn.15816.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"943_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","volume":"23","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23(4):322. https:\/\/doi.org\/10.1097\/PEP.0b013e3182351f04.","journal-title":"Pediatr Phys Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00943-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:38Z","timestamp":1784819498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00943-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00943-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lisa Belter and Mary Curry are employees of Cure SMA, which has received funding from the SMA industry collaboration (SMA-IC) for other distinct projects. These authors have no competing personal interests. Mary Schroth was an employee of Cure SMA at the time of writing. Kendra Lawrence has received financial compensation from Cure SMA for research activities, including work related to this study. Casey Tak has no conflicts of interests to declare.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board (IRB) approval was obtained by the Western Copernicus Group (WCG) IRB (IRB ID: 20173058). This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Consent was assumed through survey participation. The STROBE reporting guideline for observational studies was followed.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}